These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 34232939)
1. Coexistence of a secondary STRN-ALK, EML4-ALK double-fusion variant in a lung adenocarcinoma patient with EGFR mutation: a case report. Zeng Q; Gao H; Zhang L; Qin S; Gu Y; Chen Q Anticancer Drugs; 2021 Sep; 32(8):890-893. PubMed ID: 34232939 [TBL] [Abstract][Full Text] [Related]
2. Responder of Gefitinib Plus Crizotinib in Osimertinib Failure EGFR-mutant NSCLC-Resistant With Newly Identified STRN-ALK by Next-Generation Sequencing. Zhou C; Zeng L; Zhang Y; Yang N J Thorac Oncol; 2019 Jul; 14(7):e143-e144. PubMed ID: 31235037 [No Abstract] [Full Text] [Related]
3. Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations. Yang X; Zhong J; Yu Z; Zhuo M; Zhang M; Chen R; Xia X; Zhao J BMC Cancer; 2021 Oct; 21(1):1107. PubMed ID: 34654390 [TBL] [Abstract][Full Text] [Related]
4. Detection of an EML4-ALK fusion mutation secondary to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer: a case report. Ren KH; Qin WW; Wang Y; Peng JC; Hu WX Ann Palliat Med; 2022 Jul; 11(7):2503-2509. PubMed ID: 35927783 [TBL] [Abstract][Full Text] [Related]
5. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma. Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596 [TBL] [Abstract][Full Text] [Related]
6. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer. Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691 [TBL] [Abstract][Full Text] [Related]
7. Acquired EML4-ALK fusion and EGFR C797S in cis mutation as resistance mechanisms to osimertinib in a non-small cell lung cancer patient with EGFR L858R/T790M. Wang LS; Chen SQ; Zhong X; Jiao XD; Liu K; Qin BD; Wu Y; Ling Y; Duan XP; Zang YS Anticancer Drugs; 2023 Nov; 34(10):1146-1150. PubMed ID: 36728908 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1-ALK fusion. Yin Q; Guo T; Zhou Y; Sun L; Meng M; Ma L; Wang X Thorac Cancer; 2022 Feb; 13(4):637-642. PubMed ID: 34964276 [TBL] [Abstract][Full Text] [Related]
9. Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance. Xu Y; Zhang F; Pan X; Wang G; Zhu L; Zhang J; Wen D; Lu S Cancer Commun (Lond); 2018 May; 38(1):19. PubMed ID: 29764505 [TBL] [Abstract][Full Text] [Related]
10. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene. Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107 [TBL] [Abstract][Full Text] [Related]
11. miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC. Lai Y; Kacal M; Kanony M; Stukan I; Jatta K; Kis L; Norberg E; Vakifahmetoglu-Norberg H; Lewensohn R; Hydbring P; Ekman S Biochem Biophys Res Commun; 2019 Apr; 511(2):260-265. PubMed ID: 30791979 [TBL] [Abstract][Full Text] [Related]
12. [A Case of Non-small Cell Lung Cancer Treated with Three ALK Inhibitors and Chemotherapy]. Wang J; Xu X; Sun Y; Li H Zhongguo Fei Ai Za Zhi; 2021 May; 24(5):372-376. PubMed ID: 34034462 [TBL] [Abstract][Full Text] [Related]
13. A rare KIF5B-ALK fusion variant in a lung adenocarcinoma patient who responded to crizotinib and acquired the ALK L1196M mutation after resistance: a case report. Zeng H; Liu Y; Wang W; Tang Y; Tian P; Li W Ann Palliat Med; 2021 Jul; 10(7):8352-8357. PubMed ID: 33832282 [TBL] [Abstract][Full Text] [Related]
14. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR. Wu SG; Kuo YW; Chang YL; Shih JY; Chen YH; Tsai MF; Yu CJ; Yang CH; Yang PC J Thorac Oncol; 2012 Jan; 7(1):98-104. PubMed ID: 22124476 [TBL] [Abstract][Full Text] [Related]
15. STRN-ALK Fusion in Lung Adenocarcinoma with Brain Metastasis Responded Well to Ensartinib: A Case Report. Zhang L; Xiao P; Meng F; Zhong D Curr Oncol; 2022 Sep; 29(10):6749-6753. PubMed ID: 36290807 [TBL] [Abstract][Full Text] [Related]
16. Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib. Guo W; Liang J; Zhang D; Huang X; Lv Y Medicine (Baltimore); 2022 Oct; 101(40):e30913. PubMed ID: 36221356 [TBL] [Abstract][Full Text] [Related]
17. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity. Kimura H; Nakajima T; Takeuchi K; Soda M; Mano H; Iizasa T; Matsui Y; Yoshino M; Shingyoji M; Itakura M; Itami M; Ikebe D; Yokoi S; Kageyama H; Ohira M; Nakagawara A Lung Cancer; 2012 Jan; 75(1):66-72. PubMed ID: 21757253 [TBL] [Abstract][Full Text] [Related]
18. Characterization of thyroid cancer driven by known and novel ALK fusions. Panebianco F; Nikitski AV; Nikiforova MN; Kaya C; Yip L; Condello V; Wald AI; Nikiforov YE; Chiosea SI Endocr Relat Cancer; 2019 Nov; 26(11):803-814. PubMed ID: 31539879 [TBL] [Abstract][Full Text] [Related]
19. Frequency, clinical features and differential response to therapy of concurrent Liu J; Mu Z; Liu L; Li K; Jiang R; Chen P; Zhou Q; Jin M; Ma Y; Xie Y; Xiang J; Li B; Ma Y; Mao X; Zhang L; Zhang T; Wu D Drug Des Devel Ther; 2019; 13():1809-1817. PubMed ID: 31213769 [No Abstract] [Full Text] [Related]
20. Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: A case report. Li Z; Li P; Yan B; Gao Q; Jiang X; Zhan Z; Yan Q; Lizaso A; Huang C Thorac Cancer; 2020 Jan; 11(1):176-180. PubMed ID: 31766077 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]